- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02253277
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (CoRNea)
A Phase Ib Single-arm, Open-label, Multicenter Study to Assess the Safety and Tolerability of Combined Treatment With Nilotinib 300mg BID and Ruxolitinib Increasing Dose in CML and Ph+ ALL Patients
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Berlin, Tyskland, 13353
- Novartis Investigative Site
-
Frankfurt, Tyskland, 60590
- Novartis Investigative Site
-
Jena, Tyskland, 07740
- Novartis Investigative Site
-
Leipzig, Tyskland, 04103
- Novartis Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Patients of the first stratum must have chronic myeloid leukemia receiving nilotinib first-line therapy or receiving second-line or subsequent-line treatment with nilotinib.
Patients of the second stratum must have CML in AP/BC or relapsed/refractory Ph+ ALL, or be Ph+ ALL patients with MRD with or without prior nilotinib pretreatment;
Patients must have adequate end organ function, as defined by:
- Creatinine < 2.0 x upper limit of normal (ULN)
- Total bilirubin < 1.5 x ULN (< 3.0 x ULN if related to disease or polymorphism, such as Mb. Gilbert)
- ALT and AST < 2.5 x ULN (< 5.0 x ULN if related to disease)
- Serum lipase ≤ 1.5 x ULN
- Alkaline phosphatase ≤ 2.5 x ULN (< 5.0 x ULN if related to disease);
Patients must have the following electrolyte values within normal limits or corrected to within normal limits with supplements prior to the first dose of study medication:
- Potassium
- Magnesium
- Phosphate
- Total calcium (corrected for serum albumin);
Female patients of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days before initiation of study drug. All WOCBP must use highly effective contraceptive methods throughout and during 3 months after study;
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 for patients in CP, ≤ 2 for patients in AP/BC or with relapsed/refractory Ph+ ALL or with Ph+ ALL with MRD;
Patient has the following laboratory values within 7 days of starting study drug:
- For CML and Ph+ ALL patients: platelet count > 75 x 109/L and ANC > 1.0 x 109/L
Exclusion Criteria:
Patient must not have evidence of active malignancy other than the existing CML or ALL
Patient must not receive drugs that interfere with coagulation or inhibits platelet function, with the exception of aspirin ≤ 150 mg per day or low molecular weight heparin.
Patient must not have history of platelet dysfunction, bleeding diathesis, and/or coagulopathy in the 6 months prior to screening;
Patient must not require treatment with any strong CYP3A4 inducer or inhibitor
Patient must not have history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes and their excipients;
Patients must not take other investigational drugs within 28 days prior to screening;
Patient must not be pregnant or lactating at screening and/or baseline;
Patient must not have impaired cardiac functions
Other protocol-defined inclusion/exclusion criteria may apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Nilotinib and Ruxolitinib
The study included two strata, which were to be treated in parallel.
The first stratum consisted of CML-patients in CP, which had been on nilotinib treatment before entering the study.
These patients did not optimally respond to the previous treatment.
The second stratum consisted of patients with CML in AP or BC and patients with relapsed/refractory Ph+ ALL and Ph+ ALL patients with MRD, with or without previous nilotinib treatment.
Patients were treated with 300mg nilotinib BID during the escalation phase (12 months) with increasing doses of ruxolitinib.
The dose expansion phase (12 months) began following the determination of the MTD of the combination and the decision to explore the cohort for confirmation of RPIID.
In this phase, safety and tolerability of the MTD and/or potential RPIID was to be further evaluated, with the purpose of establishing that this dose is suitable for use in this patient group.
|
Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules.
Nilotinib was not dosed by weight or body surface area.
Medication labels were in German and complied with the legal requirements of Germany.
They included storage conditions for the drug but no information about the patient.
The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.
Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets.
Medication labels were in German and complied with the legal requirements of Germany.
They included storage conditions for the drug but no information about the patient.
The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Occurrence of dose limiting toxicities (DLTs)
Tidsramme: Baseline, up to day 28 (equals first cycle)
|
Occurrence of DLTs during cycle 1
|
Baseline, up to day 28 (equals first cycle)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Safety and tolerability profile of nilotinib and ruxolitinib administered in combination
Tidsramme: Baseline, up to month 12
|
Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RPIID) of ruxolitinib in combination with nilotinib.
(timeframe, baseline up to month 12)
|
Baseline, up to month 12
|
Trough levels of nilotinib and ruxolitinib administered in combination
Tidsramme: Baseline, up to month 12
|
Trough levels will be determined by measuring the minimum plasma concentration (Cmin).
|
Baseline, up to month 12
|
Clinical activity of nilotinib and ruxolitinib administered in combination
Tidsramme: Baseline and at 3, 6, and 12 months
|
Chronic myeloid leukemia in chronic phase: assessment of molecular response: MMR (≤0.1% BCR-ABL) and MR4 (≤0.001%
BCR-ABL) at 3, 6, 12 months; Advanced disease: assessment of cytogenetic response will be based on evaluating percentage of Ph+ metaphases
|
Baseline and at 3, 6, and 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Andreas Hochhaus, Prof. Dr. med., Universitatsklinikum Jena
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CAMN107YDE19
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Kronisk myeloid leukemi
-
University of PennsylvaniaAktiv, ikke rekrutterendeAkutt myeloid leukemi, i tilbakefall | Akutt myeloid leukemi, refraktær | Akutt myeloid leukemi, pediatriskForente stater
-
Betta Pharmaceuticals Co., Ltd.Har ikke rekruttert ennåAkutt Myeloid Leukemi LeukemiKina
-
Washington University School of MedicineTilbaketrukketRefraktær Akutt Myeloid Leukemi | Tilbakefallende akutt myeloid leukemiForente stater
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.AvsluttetAkutt myeloid leukemi | Refraktær Akutt Myeloid Leukemi | Tilbakefallende akutt myeloid leukemiForente stater
-
Xuzhou Medical UniversityRekrutteringAkutt myeloid leukemi, i tilbakefall | Akutt myeloid leukemi refraktærKina
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.RekrutteringStudie av APG2575 enkeltmiddel og kombinasjon med terapi hos pasienter med tilbakefall/refraktær AMLMyeloid malignitet | Tilbakefallende/Refraktær Akutt Myeloid LeukemiKina
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RekrutteringAkutt myeloid leukemi, i tilbakefall | Akutt myeloid leukemi refraktærKina
-
Xuzhou Medical UniversityRekrutteringAkutt myeloid leukemi, i tilbakefall | Akutt myeloid leukemi refraktærKina
-
Bio-Path Holdings, Inc.RekrutteringAkutt myeloid leukemi, i tilbakefall | Akutt myeloid leukemi refraktærForente stater
-
Beijing Boren HospitalRekrutteringAkutt myeloid leukemi | Refraktær Akutt Myeloid Leukemi | Tilbakefall leukemiKina
Kliniske studier på Nilotinib
-
Niguarda HospitalFullførtLeukemi, Myeloid, Kronisk faseItalia
-
Novartis PharmaceuticalsAvsluttetPulmonal arteriell hypertensjonSveits, Forente stater, Tyskland, Singapore, Korea, Republikken, Canada
-
Georgetown UniversityUkjentParkinsons sykdom | Parkinsons sykdom med demensForente stater
-
Shenzhen Second People's HospitalDongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The Affiliated Hospital of Guangdong Medical College og andre samarbeidspartnereRekrutteringKronisk myeloid leukemi, kronisk fase | NilotinibKina
-
Andrew J. Wagner, MD, PhDMassachusetts General Hospital; Novartis; Brigham and Women's HospitalAktiv, ikke rekrutterendeTenosynovial kjempecelletumor | Pigmentert villonodular synovitt | Diffus type kjempecelletumorForente stater
-
Novartis PharmaceuticalsIkke lenger tilgjengeligHypereosinofilt syndrom (HES)
-
KeifeRx, LLCWorldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals...Har ikke rekruttert ennå
-
Novartis PharmaceuticalsIkke lenger tilgjengelig
-
Novartis PharmaceuticalsFullført